$1,000 Invested in Eli Lilly 5 Years Ago Is Now Worth Over $5,000. Could It Soar That Much Again by 2031?

Source The Motley Fool

Key Points

  • Eli Lilly has seen revenue explode higher in recent years thanks to its dominance in the weight loss drug market.

  • Its weight loss portfolio drove double-digit revenue growth in the recent quarter.

  • 10 stocks we like better than Eli Lilly ›

Eli Lilly (NYSE: LLY) is a well-established pharmaceutical company, known for delivering reliable revenue year after year. Patients need their medicines regardless of the economic backdrop, and this fact offers pharma giants a certain amount of stability. This translates into an element of safety for investors.

But Eli Lilly also offers something that many of us associate with other industries, such as technology. I'm talking about growth. The company has generated double-digit revenue gains in recent quarters thanks to its presence in the weight loss drug space. Lilly sells tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss. (Doctors have prescribed either one for the weight loss indication.)

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

All of this helped the stock climb more than 420% over the past five years, meaning that if you invested $1,000, you would have over $5,000 today. Could it soar that much again by 2031? Let's find out.

An investor works on a laptop at home.

Image source: Getty Images.

Eli Lilly's GLP-1 drugs

So, first, let's take a look at Eli Lilly's path over the past few years. This pharma giant sells a broad range of medicines across treatment areas, from cancer to migraine and Alzheimer's disease. But the area that has stood out in recent years is weight loss. Lilly's drugs are in the class known as GLP-1. These drugs act on hormonal pathways involved in digestion and therefore regulate appetite and blood sugar levels.

Individuals aiming to lose weight have rushed to get in on GLP-1 drugs since they've proven safety and efficacy and are easy to self-administer. Mounjaro and Zepbound are weekly injections, and Lilly recently won approval for a new GLP-1 drug in pill format. That product is called Foundayo and may significantly broaden the audience for these types of drugs.

Lilly isn't alone in the market; in fact, it wasn't even the leader in the early days of GLP-1 drugs. Novo Nordisk was the original leader, though Lilly slipped ahead in 2025. Now, the two are vying for leadership in the oral GLP-1 space, as Novo also launched an oral drug this year.

Lilly's recent earnings report demonstrates the power of its GLP-1 drugs, with Mounjaro and Zepbound driving a 39% increase in revenue to more than $24 billion.

What's next for Eli Lilly

The story doesn't end here, though. Lilly also has an extensive pipeline of weight loss drug candidates, including one called retatrutide that's in phase 3 studies and may have the potential to deliver greater weight loss. This could complement the existing portfolio, offering a variety of GLP-1 options for different needs.

Now, let's consider whether an investment in Lilly could once again turn $1,000 into $5,000 over the coming five years. This would imply a gain of about 420%, taking the share price to about $7,092 -- and the market cap from $1.2 trillion today to $6.3 trillion. This surpasses the value of today's biggest technology leaders.

Of course, it's possible that over the coming five years, tech players also will gain, seeing their market values march higher. So the market as a whole may see value climb significantly, making the Lilly jump to more than $6 trillion seem less shocking.

That said, after the S&P 500's 78% increase over the past three calendar years and the double- and triple-digit gains of many big stocks, I wouldn't count on the same momentum over the coming five years -- for the general market or for Lilly. This doesn't mean the market or Lilly will drop. I think there's still potential for gains, and Lilly's weight loss portfolio and potentially new launches from the pipeline could drive significant growth.

Though I would be surprised to see another gain of 400%, I think it's possible to see a double- or triple-digit increase from Lilly stock over the next five years -- and that means I consider it a great buy today.

Should you buy stock in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 2, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 2, 2026. Read on for the details.
Author  Mitrade
Nov 02, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 2, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
Nov 18, Wed
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
Nov 19, Thu
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
Nov 19, Thu
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 20, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
Author  Mitrade
Nov 20, Fri
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
goTop
quote